The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?
- PMID: 22338019
- DOI: 10.1158/1078-0432.CCR-12-0409
The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?
Abstract
Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients' unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity.
©2012 AACR.
Comment on
-
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.Clin Cancer Res. 2012 Apr 1;18(7):2039-47. doi: 10.1158/1078-0432.CCR-11-1823. Epub 2012 Jan 23. Clin Cancer Res. 2012. PMID: 22271879 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical